HK Stock Market Move | DIAGENS-B(02526) surged over 24% in morning trading; iMed-6.0 swept the top two spots on two international leaderboards; Forbes published an article benchmarking it against U.S.-listed Tempus AI.

date
10:19 16/11/2026
avatar
GMT Eight
DIAGENS-B(02526) surged over 24% in morning trading. As of press time, it was up 24.35% at HK$105.7, with a turnover of HK$62.7362 million.
DIAGENS-B(02526) rose over 24% in morning trading. As of press time, it was up 24.35% at HK$105.7, with a turnover of HK$62.7362 million. On the news front, Diagens recently released iMedImage6.0, its sixth-generation general medical imaging large model with a completely rebuilt underlying architecture. On the two most authoritative international evaluation benchmarks, MMMU and MedBench VLM, iMed-6.0 swept the global No. 1 and No. 2 spots, comprehensively outperforming GPT-4V, GPT-5.5, Gemini-3.5-Flash, Claude Opus4.7 and mainstream domestic general large models. The series release caused a sensation on overseas social platforms, with a single post surpassing 853,000 views in less than 24 hours. It is worth noting that the internationally authoritative financial media outlet Forbes recently published an in-depth long-form article titled "How Chinese Medical AI Is Winning Back the Market," listing Diagens Technology as the core touchstone for the value re-rating of Chinese medical AI and benchmarking it in depth against Tempus AI, the leading medical AI company whose U.S.-listed shares have surged 90% this year. Forbes emphasized that Diagens Technology is building the "Microsoft Office of medical AI" through its zero-code platform iMedLoop.